跳至主要内容
临床试验/EUCTR2006-000977-31-BE
EUCTR2006-000977-31-BE进行中(未招募)1 期

PHASE IIIB, RANDOMIZED, OPEN LABEL STUDY OF PEGYLATED INTERFERON ALFA-2A IN COMBINATION WITH LAMIVUDINE OR ENTECAVIR COMPARED WITH UNTREATED CONTROL PATIENTS IN CHILDREN WITH HBEAG POSITIVE CHRONIC HEPATITIS B IN THE IMMUNE TOLERANT PHASE

F. Hoffmann-La Roche Ltd0 个研究点目标入组 59 人开始时间: 2015年10月1日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
入组人数
59

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • Male and female patients 3 to less than 18 years of age at baseline (12< 18 years of age at baseline in Russia and India)
  • Positive for HBsAg and HBeAg for more than 6 months prior to baseline
  • Detectable HBV-DNA (> 20,000 IU/mL as measured by PCR or hybridization) on at least 2 occasions at least one month apart with the latest determination obtained = 42 days prior to baseline.
  • Are the trial subjects under 18? yes
  • Number of subjects for this age range: 114
  • F.1.2 Adults (18-64 years) no
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • Patients who have had any previous anti-HBV treatment, or who are co-infected with hepatitis A virus (HAV), HCV, hepatitis D virus (HDV) or HIV, or who have decompensated liver disease will beexcluded.

研究者

相似试验

进行中(未招募)
1 期
A Study of Pegasys in Combination with antiviral HBV oral Lamivudine or entecavir compared against no treatment in Children Positive buttolerant to Chronic Hepatitis B.
EUCTR2006-000977-31-GBF. Hoffmann-La Roche Ltd114
进行中(未招募)
1 期
A Study of Pegasys in Combination with antiviral HBV oral Lamivudine or entecavir compared against no treatment in Children Positive buttolerant to Chronic Hepatitis B.Chronic Hepatitis B Virus infection in children.MedDRA version: 20.0Level: LLTClassification code 10019743Term: Hepatitis B virus (HBV)System Organ Class: 100000004848
EUCTR2006-000977-31-ITF. HOFFMANN - LA ROCHE LTD.59
进行中(未招募)
1 期
A Study of Pegasys in Combination with antiviral HBV oral Lamivudine or Entecavir compared against no treatment in Children Positive but tolerant to Chronic Hepatitis B.Chronic Hepatitis B Virus infectionMedDRA version: 20.0Level: LLTClassification code 10019743Term: Hepatitis B virus (HBV)System Organ Class: 100000004848
EUCTR2006-000977-31-DEF. Hoffmann-La Roche Ltd59
招募中
不适用
A PHASE IIIB, RANDOMIZED, OPEN-LABEL STUDY OF THE SAFETY AND EFFICACY OF DOLUTEGRAVIR OR EFAVIRENZ EACH ADMINISTERED WITH TWO NRTIS IN HIV-1-INFECTED ANTIRETROVIRAL THERAPY-NAÏVE ADULTS STARTING TREATMENT FOR RIFAMPICIN-SENSITIVE TUBERCULOSIS
PER-069-14ViiV Healthcare UK Limited,14
尚未招募
3 期
Study of Pegylated interferon alfa-2a in combination with Lamivudine or Entecavir in children with Chronic Hepatitis B
CTRI/2017/07/009027F HoffmannLa Roche Ltd114